Boehringer Ingelheim, HealthPrize team on Spiriva Respimat support program
RIDGEFIELD, Conn. — Boehringer Ingelheim on Wednesday announced a new online program for patients treating their COPD with the company’s Spiriva Respimat. The program, RespiPoints, is being undertaken in partnership with HealthPrize Technologies.
RespiPpoints provides tools to patients to help improve healthy behaviours, encourage healthy habits and track medication adherence. Enrolled patients can earn points that can be redeemed for e-gift cards through such activities as reporting they took their daily Spiriva Respimat dose, verifying their monthly refill, reading educational materials about COPD and completing weekly quizzes and surveys.
“Boehringer Ingelheim is committed to providing support and resources for patients’ needs beyond our industry-leading six COPD medicines,” Boehringer Ingelheim executive director and head of business innovation Ruchin Kansal said. “We are proud to continue our unwavering commitment to the COPD community with new technology and support services that can help improve patient outcomes. The RespiPoints program is the latest in a series of efforts to empower people living with COPD to better manage their health with tools that are engaging and educational”
NACDS Congressional statement urges provider status, MTM
ARLINGTON, Va. – The National Association of Chain Drug Stores issued a statement Wednesday urging members of the U.S. House of Representatives Ways and Means Subcommittee on Health to focus on policies and innovations that will improve healthcare access and foster healthcare-delivery partnerships by supporting provider status legislation.
“The role pharmacists are playing in healthcare delivery continues to expand. In addition to medication adherence services, pharmacists are on the frontline of providing access to health tests, helping patients manage chronic health conditions and expanding immunization services,” stated Steven Anderson, NACDS president and CEO. “Expanding access to pharmacist services is a key component to reducing healthcare costs and improving patient outcomes.”
As part of its commitment to strengthening and improving Medicare, NACDS asked the Subcommittee to support bipartisan legislation — H.R. 592/S. 314, the Pharmacy and Medically Underserved Areas Enhancement Act — which would increase access to pharmacist-provided services to underserved Medicare beneficiaries, within pharmacists’ scope of practice.
The legislation has been cosponsored by more than 65% of the U.S. House of Representatives and 45% of the U.S. Senate.
NACDS also voiced support for the Center for Medicare and Medicaid Innovation’s Enhanced Medication Therapy Management Model Pilot, which would improve the Part D MTM program by increasing outreach and targeting strategies, and ensuring services are in line with beneficiaries’ needs. NACDS urged the lawmakers to help ensure the inclusion of retail community pharmacists in the pilot program to enhance its potential for success.
Because the CMMI Enhanced MTM Model Pilot will begin in 2017, NACDS asked lawmakers to support S. 776, the Medication Therapy Management Empowerment Act of 2015, which would give MTM access to beneficiaries with chronic conditions in the short term before the pilot is implemented.
Takeda, Ultragenyx partner to develop rare genetic disease treatments
NOVATO, Calif. and OSAKA, Japan — Takeda on Tuesday announced a new partnership with Ultragenyx Pharmaceutical to develop and commercialize therapies for rare genetic diseases.
Under the partnership, Ultragenyx will initially receive an exclusive license for one of Takeda’s preclinical product candidates in a pre-determined field of use, along with the option to co-develop and co-commercialize the candidate in other therapeutic areas. Additionally, the two companies have established a five-year research collaboration that will give Ultragenyx the option to license as many as five Takeda product candidates for rare diseases once the companies agree on and conduct initial validation activities under a joint research committee.
“This broad collaboration provides Ultragenyx with a product opportunity that is approaching clinical-stage development as well as a potential continued source of new product candidates that will help us achieve our goal of bringing a new therapy into the clinic every one to two years,” Ultragenyx CEO Emil Kakkis said. “Takeda has an impressive early pipeline of therapies with potential across a number of rare genetic diseases, and we are pleased that Takeda has chosen to partner with us to bring these therapies to patients with rare diseases that have few or no treatment options.”
Takeda will have the exclusive option to commercialize any licensed products that are the result of the collaboration in Asia and it will have the option to exclusively license one Ultragenyx pipeline products in Japan. Takeda will invest up to $65 million in Ultragenyx in two tranches, the first of which will be a $25 million stock purchase and $15 million cash premium at closing. Ultragenyx’s option will see a second equity purchase of 25 million with no additional premium. No additional financial details were disclosed.
“Ultragenyx is a rapidly emerging rare disease company, led by a highly experienced and successful management team,” Takeda chief medical and scientific officer Dr. Andrew Plump said. “This partnership provides Takeda access to Ultragenyx's strong patient-centric development and regulatory capabilities in the rare disease space, and could create significant value for both companies by delivering important new therapies to patients.”
Loading Post Please Wait...